Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a milk protein cream soothe Kids' eczema?

NCT ID NCT07259343

Symptom relief Sponsor: Universidad Autónoma de Aguascalientes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether a cream made with glycomacropeptide, a milk protein, can reduce eczema symptoms in children aged 2 to 12 with mild atopic dermatitis. Twenty children will apply either the glycomacropeptide cream or a standard moisturizer twice daily for four weeks. Researchers will track changes in skin severity, itching, sleep quality, and skin bacteria levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
glycomacropeptide cream
What this could lead to
If it works, this could point toward a new topical option to reduce itching and skin severity in children with mild eczema.
What could go wrong
This is a very small pilot study with only 20 children, so results may not apply broadly. The cream may not outperform a standard emollient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged between 2 and 12 years. * Clinical diagnosis of atopic dermatitis according to Hanifin and Rajka criteria. * Mild atopic dermatitis with SCORAD \<25 points. * Written informed consent signed by parents or legal guardian. Exclusion Criteria: * Age younger than 2 years or older than 12 years. * Moderate to severe atopic dermatitis (SCORAD \>25 points). * Presence of other dermatoses in addition to atopic dermatitis. * Background of hypersensitivity or anaphylaxis to any components of the vehicle cream. * Allergy or hypersensitivity to glycomacropeptide. * Inability to attend follow-up medical consultations or to adhere to the treatment schedule. * Any clinical reason determined by the clinical investigator that makes the child unsuitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis (AD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Universidad Autónoma de Aguascalientes

    RECRUITING

    Aguascalientes, Aguascalientes, 20100, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.